Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2292-2025

Bartels ELISA Legionella Urinary Antigen. Recall

Bartels ELISA Legionella Urinary Antigen. Model Number: B1029-440. In Vitro Diagnostic test kit for the presumptive diagnosis of past or current Legionnaires Disease.

FDA recall Class II

Ongoing

FDA lists this Class II recall for Bartels ELISA Legionella Urinary Antigen.. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2292-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jul 22, 2025
FDA report date
Aug 20, 2025
Quantity in commerce
968 kits
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Bartels ELISA Legionella Urinary Antigen. Model Number: B1029-440. In Vitro Diagnostic test kit for the presumptive diagnosis of past or current Legionnaires Disease.

Affected model & UDI checker

Search the exact identifiers published for Z-2292-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
B1029-440Bartels ELISA Legionella Urinary Antigen.Check source noticeNot specified
Not specifiedBartels ELISA Legionella Urinary Antigen.Check source notice05391516744065
FDA code information

Model Number: B1029-440. UDI-DI: 05391516744065. Lot Numbers: 065 and 066

View the original FDA recall notice

Why was this product recalled?

Potential for Bartels ELISA Legionella Urinary Antigen kit B1029-440 lot 065 and 066 to contain particulate matter.

These are potential consequences described in the source. The recall reason does not establish how many injuries or incidents occurred.

What actions did Trinity Biotech USA take?

Trinity Biotech initially notified consignees 06/05/2025 via letter. Consignees were instructed to inspect the conjugate bottles before use in both manual and automated testing and if any are observed with particulate matter, Trinity Biotech confirms the kit performs, and results are consistent with release specifications and IFU claims. However, replacement can be requested. Trinity Biotech notified consignees again on about 07/22/2025 via an updated URGENT: MEDICAL DEVICE Notification letter. Consignees were instructed that their trained laboratory technicians should inspect the conjugate bottles before use in both manual and automated testing, if any bottle is observed to contain conjugate with particulate matter, to discard the bottle and use a clear bottle available. If there are no other available clear bottles, please contact Trinity Biotech for a replacement kit. The current conjugate will be replaced with Bartels ELISA Legionella Urinary Antigen kit B1029-440 lot 067 once available.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology